B11. Building Cross-functional Excellence
Tracks
Reimbursement/Market Access
| Wednesday, June 4, 2025 |
| 1:30 PM - 2:30 PM |
| C2.4 |
Chair & Speakers
Matt Britland
Director of Business Development
Medwise
Building Cross-functional Excellence: From Silos to Strategy – Getting It Right for Faster, Fairer Access
Abstract
Cross-functional excellence is no longer just a competency—it's a strategic imperative and licence to operate. But how do we move from good intentions to bold execution?
This session brings together four diverse perspectives—from consulting, biotech, industry advocacy, and pharmaceuticals—to explore what’s working, what’s broken, and what needs to evolve across Medical Affairs, Regulatory, Market Access, and Commercial. Expect practical tools, candid insights, live polling, and some constructive controversy.
We’ll challenge the idea that collaboration is just about alignment. We’ll examine how to:
• Reduce market access timelines
• Embed clinician and lived experience meaningfully
• Ensure shared ownership of QUM
• Build mindsets, behaviours, and processes that scale across therapy areas and organisational complexity
This session brings together four diverse perspectives—from consulting, biotech, industry advocacy, and pharmaceuticals—to explore what’s working, what’s broken, and what needs to evolve across Medical Affairs, Regulatory, Market Access, and Commercial. Expect practical tools, candid insights, live polling, and some constructive controversy.
We’ll challenge the idea that collaboration is just about alignment. We’ll examine how to:
• Reduce market access timelines
• Embed clinician and lived experience meaningfully
• Ensure shared ownership of QUM
• Build mindsets, behaviours, and processes that scale across therapy areas and organisational complexity
Biography
Dr Amanda Ruth
Director Corporate Affairs, Access And Policy
Apellis Australia Pty Ltd
Building Cross-functional Excellence: From Silos to Strategy – Getting It Right for Faster, Fairer Access
Abstract
Cross-functional excellence is no longer just a competency—it's a strategic imperative and licence to operate. But how do we move from good intentions to bold execution?
This session brings together four diverse perspectives—from consulting, biotech, industry advocacy, and pharmaceuticals—to explore what’s working, what’s broken, and what needs to evolve across Medical Affairs, Regulatory, Market Access, and Commercial. Expect practical tools, candid insights, live polling, and some constructive controversy.
We’ll challenge the idea that collaboration is just about alignment. We’ll examine how to:
• Reduce market access timelines
• Embed clinician and lived experience meaningfully
• Ensure shared ownership of QUM
• Build mindsets, behaviours, and processes that scale across therapy areas and organisational complexity
This session brings together four diverse perspectives—from consulting, biotech, industry advocacy, and pharmaceuticals—to explore what’s working, what’s broken, and what needs to evolve across Medical Affairs, Regulatory, Market Access, and Commercial. Expect practical tools, candid insights, live polling, and some constructive controversy.
We’ll challenge the idea that collaboration is just about alignment. We’ll examine how to:
• Reduce market access timelines
• Embed clinician and lived experience meaningfully
• Ensure shared ownership of QUM
• Build mindsets, behaviours, and processes that scale across therapy areas and organisational complexity
Biography
Heather Wrightman
Senior Manager, Access And Funding Policy
Medicines Australia
Building Cross-functional Excellence: From Silos to Strategy – Getting It Right for Faster, Fairer Access
Abstract
Cross-functional excellence is no longer just a competency—it's a strategic imperative and licence to operate. But how do we move from good intentions to bold execution?
This session brings together four diverse perspectives—from consulting, biotech, industry advocacy, and pharmaceuticals—to explore what’s working, what’s broken, and what needs to evolve across Medical Affairs, Regulatory, Market Access, and Commercial. Expect practical tools, candid insights, live polling, and some constructive controversy.
We’ll challenge the idea that collaboration is just about alignment. We’ll examine how to:
• Reduce market access timelines
• Embed clinician and lived experience meaningfully
• Ensure shared ownership of QUM
• Build mindsets, behaviours, and processes that scale across therapy areas and organisational complexity
This session brings together four diverse perspectives—from consulting, biotech, industry advocacy, and pharmaceuticals—to explore what’s working, what’s broken, and what needs to evolve across Medical Affairs, Regulatory, Market Access, and Commercial. Expect practical tools, candid insights, live polling, and some constructive controversy.
We’ll challenge the idea that collaboration is just about alignment. We’ll examine how to:
• Reduce market access timelines
• Embed clinician and lived experience meaningfully
• Ensure shared ownership of QUM
• Build mindsets, behaviours, and processes that scale across therapy areas and organisational complexity
Biography
Jon Zdon
Medical Head Of Governance And Excellence
Novartis
Building Cross-functional Excellence: From Silos to Strategy – Getting It Right for Faster, Fairer Access
Abstract
Cross-functional excellence is no longer just a competency—it's a strategic imperative and licence to operate. But how do we move from good intentions to bold execution?
This session brings together four diverse perspectives—from consulting, biotech, industry advocacy, and pharmaceuticals—to explore what’s working, what’s broken, and what needs to evolve across Medical Affairs, Regulatory, Market Access, and Commercial. Expect practical tools, candid insights, live polling, and some constructive controversy.
We’ll challenge the idea that collaboration is just about alignment. We’ll examine how to:
• Reduce market access timelines
• Embed clinician and lived experience meaningfully
• Ensure shared ownership of QUM
• Build mindsets, behaviours, and processes that scale across therapy areas and organisational complexity
This session brings together four diverse perspectives—from consulting, biotech, industry advocacy, and pharmaceuticals—to explore what’s working, what’s broken, and what needs to evolve across Medical Affairs, Regulatory, Market Access, and Commercial. Expect practical tools, candid insights, live polling, and some constructive controversy.
We’ll challenge the idea that collaboration is just about alignment. We’ll examine how to:
• Reduce market access timelines
• Embed clinician and lived experience meaningfully
• Ensure shared ownership of QUM
• Build mindsets, behaviours, and processes that scale across therapy areas and organisational complexity
Biography
